|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression analyses showed that elevated YKL-40 (hazard ratio (HR) = 5.6, P = 0.001), elevated glucose (HR = 3.6, P = 0.001), and schizophrenia diagnosis (HR = 3.0, P = 0.014) at baseline were associated with subsequent development of type 2 diabetes.
|
30328100 |
2019 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Further studies are required to perceive a role of YKL-40 and MCP-1 in the initiation and progression of schizophrenia.
|
30132802 |
2018 |
|
Schizophrenia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that higher serum YKL-40 levels are associated with personality trait in patients with schizophrenia.
|
22366530 |
2012 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we report that CHI3L1 SNPs, shown to be involved in the predisposition of schizophrenia, are not associated with rheumatoid arthritis.
|
20300754 |
2011 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allelic expression imbalance of the schizophrenia susceptibility gene CHI3L1: evidence of cis-acting variation and tissue specific regulation.
|
21642896 |
2011 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the genetic variants in the CHI3L1 gene have ethnic heterogeneity and confer a susceptibility to schizophrenia in Asian populations.
|
20051317 |
2010 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that the genetic contribution of CHI3L1 to schizophrenia is variable, even though it is mechanistically involved in the disease process.
|
18767121 |
2009 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings support a functional mechanism for involvement of CHI3L1 in schizophrenia susceptibility, possibly contributing to a less severe illness.
|
18281018 |
2008 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Our findings identify CHI3L1 as a potential schizophrenia-susceptibility gene and suggest that the genes involved in the biological response to adverse environmental conditions are likely to play roles in the predisposition to schizophrenia.
|
17160890 |
2007 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings identify CHI3L1 as a potential schizophrenia-susceptibility gene and suggest that the genes involved in the biological response to adverse environmental conditions are likely to play roles in the predisposition to schizophrenia.
|
17160890 |
2007 |
|
Schizophrenia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
To identify genes associated with schizophrenia, DNA microarray chips were used to compare schizophrenia and control hippocampus tissues, revealing four genes with elevated expression, chondrex (or YKL-40), histamine-releasing factor, HERC2, and heat-shock 70.
|
12872291 |
2003 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma.
|
31654711 |
2020 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma.
|
31654711 |
2020 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18-1.58), ovarian cancer (HR, 2.27; 95% CI 1.69-3.06), melanoma (HR, 1.77; 95% CI 1.18-2.67), lung cancer (HR, 1.73; 95% CI 1.35-2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08-2.40) and glioblastoma (HR, 1.23; 95% CI 1.07-1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98-1.17).
|
31624472 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.
|
31561550 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18-1.58), ovarian cancer (HR, 2.27; 95% CI 1.69-3.06), melanoma (HR, 1.77; 95% CI 1.18-2.67), lung cancer (HR, 1.73; 95% CI 1.35-2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08-2.40) and glioblastoma (HR, 1.23; 95% CI 1.07-1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98-1.17).
|
31624472 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.
|
31561550 |
2019 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study identifies candidate changes in secreted proteins from NF1 deficient glioma cells that could influence the tumor microenvironment, and suggests a direct link between NF1 loss and increased tumor cell production of CHI3L1 and endoglin, two factors implicated in mesenchymal identity in glioblastoma.
|
29643433 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of The Cancer Genome Atlas confirmed a relationship between glioma NF1 status and ENG and CHI3L1 in tumor samples.
|
29643433 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study identifies candidate changes in secreted proteins from NF1 deficient glioma cells that could influence the tumor microenvironment, and suggests a direct link between NF1 loss and increased tumor cell production of CHI3L1 and endoglin, two factors implicated in mesenchymal identity in glioblastoma.
|
29643433 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |